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Melanoma, the deadliest of skin cancers, is caused by the transformation of melanocytes (pigment-producing cells) that accumulate genetic alterations, leading to abnormal 
proliferation and dissemination. The American Cancer Society estimates that ~76,690 new cases of melanoma will be diagnosed in the United States in 2013, and the incidence 
is rising. Predisposition to the disease can be influenced by an individual’s genetic background, pigmentation status, and exposure to ultraviolet light (in the case of cutaneous 
melanoma). Clinically, melanoma lesions can be classified based on location and progression, which range from benign nevi to metastatic melanoma, while tumor-node-metas-
tases (TNM) staging focuses on melanoma thickness, ulceration, lymph node burden, and visceral or nonvisceral metastases. Current classification schemes do not always 
predict survival or response to therapy; the heterogeneous genetic and molecular processes driving the disease must also be taken into account. Important driver mutations, 
their frequencies, and their prevalence in subtypes of melanomas are shown in the adjacent figure.
Key Signaling Pathways
The MAPK pathway controls cell proliferation, invasion, migration, and survival. In melanoma, MAPK signaling can be constitutively activated through alterations in membrane 
receptors or through mutations of RAS or BRAF. BRAF is mutated in ~60% of melanomas, and 90% of these mutations display a valine to glutamic acid substitution (V600E), 
causing constitutive kinase activation. Although mutations of PI3K do not occur frequently, the activity of its associated pathway is often increased in melanoma and can have 
widespread effects on numerous downstream effectors such as AKT, mTOR, NF-kB, p53, and others, all potentially contributing to a more aggressive cancer phenotype. One 
way to increase PI3K activity is via loss of PTEN through mutation, gene deletion, or promoter methylation. Other important effectors of melanoma include the melanocortin 
receptor 1 (MC1R), a melanocyte-specific G protein receptor involved in human pigmentation, UV response, and DNA damage; KIT, a tyrosine receptor for the stem cell factor 
(SCF) that plays a role in melanocyte development and has shown clinical responses to imatinib; GNAQ, which relays signals from G protein-coupled receptors and is commonly 
found mutated in uveal melanomas as an early genetic event; the microphthalmia-associated transcription factor (MITF); MDM2 or MDM4; and others.
BRAF Mutant Melanomas: Therapeutic Response and Resistance
Targeted therapies against mutant BRAF have shown efficacy in the clinic and are well tolerated. Vemurafenib, for example, has shown overall response rates of ~50% and 
median progression-free survival of 5–7 months in clinical trials. Despite these encouraging results, resistance occurs in most patients. Documented mechanisms of BRAF 
inhibitor resistance include reactivation of the MAPK pathway by CRAF, ARAF, the p61BRAF(V600E) splice variant, mutational activation of NRAS or MEK, loss of the tumor 
suppressor NF1, and activation of compensatory pathways such as the PI3K network via enhanced receptor tyrosine kinase signaling (particularly through the PDGFRb, IGF1-R, 
FGFR, HGFR, and EGFR). Data are also emerging with regards to the importance of metabolism in modulating drug response. Therapeutic strategies involving the combination 
of BRAF inhibitors with other targeted agents are currently underway to improve patient outcomes. In addition, a new study suggests that alternative treatment schedules may 
delay the emergence of drug resistance.
Immunology
Immunotherapy-mediated melanoma regressions have been reported. One strategy involves ipilimumab, a humanized antibody against CTLA-4. CTLA-4 is a key receptor in 
immunosuppression and blocking CTLA-4 in melanoma patients can stimulate the immune system. Acting in a similar way, the anti-PD-1 antibody has shown favorable and 
durable responses. Current immunotherapy endeavors also focus on the role of macrophages in promoting tumor growth and immune evasion, indicating that tumor-host inter-
actions could be valid therapeutic targets. Personalized therapies for melanoma patients are likely to benefit from both pharmacological and immunological strategies in the 
future; however, toxicities will have to be taken into consideration.
Disease Heterogeneity and Plasticity
The heterogeneity of melanoma is not only found among patients and lesions, but also within the tumors themselves. Whereas studies point to the ability of all single melanoma 
cells to form tumors, evidence suggests that these cells can exist in distinct epigenetic states, display different properties, and are dynamically regulated. For example, JARID1B-
high cells are slow cycling, resistant to challenging environments such as hypoxia and drug treatment, and essential for tumor maintenance.
Melanoma Models for Biological and Therapeutic Studies
Resources to conduct melanoma studies include (1) extensive libraries of genetically characterized and distinct human-derived melanoma cell lines, (2) in vitro skin reconstructs 
that recapitulate human skin architecture, and (3) numerous mouse models that provide insights into melanoma progression, metastasis, and therapy. Exciting new models also 
include patient-derived xenografts (PDXs) in which primary tumor samples are transplanted from patients directly into animals. PDXs can be used not only to assess responses 
to therapy, but also to provide avatar models of human cancer for “coclinical” trials.
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